Evaluation of Malondialdehyde in Periodontal and Cardiovascular Disease

University of Messina

Status

Completed

Conditions

Metabolic Disease

Treatments

Other: Observation

Study type

Observational

Funder types

Other

Identifiers

NCT04030286

16-12

Details and patient eligibility

About

Malondialdehyde (MDA) plays a key role in endothelial function and may be a link for the known interaction of periodontitis and coronary heart disease (CHD). The investigators compared the impact of gingival health, periodontitis (CP), CHD or of both diseases (CP+CHD) on saliva and serum MDA levels.

Full description

The aim of this study was to evaluate a possible association between both saliva and serum MDA levels in patients with CP and with CHD and if the serum MDA levels are mediated by serum CRP

Enrollment

133 patients

Sex

All

Ages

20 to 70 years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

Presence of at least twenty teeth
CP with a minimum of 40% of sites with a clinical attachment level (CAL)

≥2mm and probing depth (PD) ≥4mm;
Presence of at least ≥2 mm of crestal alveolar bone loss verified on digital periapical radiographs
Presence of ≥40% sites with bleeding on probing (BOP)

Exclusion criteria

Intake of contraceptives
Intake of immunosuppressive or anti-inflammatory drugs throughout the last three months prior to the study
Status of pregnancy or lactation
Previous history of excessive drinking
Allergy to local anaesthetic
Intake of drugs that may potentially determine gingival hyperplasia such as Hydantoin, Nifedipine, Cyclosporin A or similar drugs.